Pharmaceutical companies often have several moving parts behind their quarterly numbers, from API demand and formulation sales to raw-material costs and export markets. Aarti Drugs is one such company, with an integrated pharmaceutical business covering APIs, formulations, specialty chemicals and intermediates.

The company started FY27 with healthy revenue and EBITDA growth, although net profit declined year over year. That makes the latest results particularly relevant for investors tracking the Aarti Drugs share price.

As of August 28, 2026, Aarti Drugs was trading at approximately ₹418.55, with a 52-week range of around ₹318.60 to ₹534.15.

What Does Aarti Drugs Do?

Aarti Drugs is a diversified pharmaceutical manufacturer with operations across active pharmaceutical ingredients (APIs), formulations, specialty chemicals and intermediates.

Its API business covers multiple therapeutic categories, including antibiotics, anti-protozoals, anti-inflammatory products, anti-diabetic products and antifungals.

The company also has a formulation business with a meaningful export component, giving it exposure to both domestic and international pharmaceutical markets.

This diversified structure is important because the company's earnings are not dependent on one pharmaceutical molecule or one end market.

Aarti Drugs Share Price: Current Market Picture

Aarti Drugs traded around ₹418.55 on August 28, 2026, according to available market data.

The stock's 52-week high was approximately ₹534.15, while the low stood near ₹318.60.

This puts the stock comfortably above its yearly low but still below its 52-week peak.

For investors, the current valuation needs to be considered alongside earnings growth. A stock's previous high does not automatically become a future target, particularly when quarterly profitability is moving differently from revenue.

Q1 FY27 Revenue Increased 19%

Aarti Drugs reported a solid increase in revenue during the June 2026 quarter.

Consolidated revenue from operations stood at approximately ₹702.78 crore, representing growth of around 19% year over year. Total income was approximately ₹703.59 crore.

Revenue was, however, down around 2.4% sequentially from the March 2026 quarter.

The year-on-year growth indicates improving business activity, while the sequential decline suggests that quarterly momentum was relatively moderate.

EBITDA Growth Was Stronger Than Revenue

One of the more positive aspects of the latest quarter was the improvement in operating profitability.

Consolidated EBITDA increased approximately 30% year over year to ₹96.9 crore, compared with ₹74.4 crore in Q1 FY26. EBITDA margin improved to around 13.8% from 12.6%.

This means the company generated considerably more operating profit despite revenue growth of about 19%.

For a pharmaceutical manufacturer, improved margins can indicate better product mix, improved realisations, operating efficiency or favourable input-cost conditions.

Net Profit Declined Despite Better EBITDA

The headline PAT number tells a different story.

Aarti Drugs reported consolidated profit after tax of approximately ₹50.13 crore, compared with ₹53.97 crore in Q1 FY26. That represents a decline of around 7% year over year.

Sequentially, PAT declined about 9% from ₹55.26 crore in Q4 FY26.

This gap between EBITDA growth and PAT performance is worth watching.

Higher depreciation, finance costs, taxes or other below-operating-line items can influence final profitability even when operating performance improves.

Therefore, investors should not look at revenue or EBITDA in isolation.

Domestic and Export Markets Both Matter

The company's standalone business generated approximately ₹627.6 crore of revenue in Q1 FY27, up 20% year over year.

Domestic sales accounted for around 68% of standalone revenue, while exports contributed approximately 32%.

Domestic revenue increased 25% year over year, while export revenue grew 12%.

The balanced exposure gives Aarti Drugs access to India's growing pharmaceutical market while retaining an international revenue stream.

Export performance can nevertheless be affected by currency movements, regulatory approvals and pricing pressure in overseas markets.

API Business Remains the Core Driver

The API business is central to Aarti Drugs' operations.

Within its API portfolio, antibiotics contributed around 35% of API sales in Q1 FY27. Anti-protozoals accounted for 18.5%, anti-diabetic products 18.2%, anti-inflammatory products 11.9% and antifungals 10.2%.

This spread across therapeutic categories gives the business some diversification.

However, APIs are also exposed to pricing cycles, competition from global manufacturers, regulatory requirements and fluctuations in raw-material costs.

Maintaining product quality while remaining cost competitive is therefore essential.

Formulations Provide Additional Growth

The formulation business generated approximately ₹81.6 crore of revenue in Q1 FY27, up 8% from ₹75.8 crore in Q1 FY26.

Exports accounted for approximately 74% of formulation revenue.

The formulation segment therefore gives Aarti Drugs another route to international growth.

Over time, increasing the contribution from higher-value formulations could potentially improve the company's product mix and earnings quality.

Specialty Chemicals Add Diversification

Aarti Drugs is not purely a pharmaceutical company.

Its specialty-chemical and intermediate operations provide exposure to industries beyond healthcare.

This diversification can be useful during periods when pharmaceutical pricing is under pressure.

At the same time, specialty chemicals have their own cycles and competitive dynamics, meaning investors need to evaluate each segment separately rather than treating the company as a single pharmaceutical business.

A Regulatory Development Investors Should Know

Aarti Drugs disclosed in July 2026 that the Gujarat Pollution Control Board had issued closure directions for its Sayakha plant, followed by revocation of the closure order on August 1, 2026.

The revocation is important because it removes the immediate operational concern associated with the closure direction.

Nevertheless, environmental and regulatory compliance remains an important factor for chemical and pharmaceutical manufacturers.

Investors should continue monitoring such developments because manufacturing interruptions can affect production and financial performance.

What Could Drive Aarti Drugs Share Price?

API Demand

Growth in pharmaceutical API demand can support higher production volumes and revenue.

Aarti Drugs' diversified therapeutic portfolio provides exposure to several areas of healthcare.

Margin Improvement

The Q1 EBITDA margin improved to around 13.8%.

If the company can maintain this improvement while increasing revenue, earnings growth could strengthen.

Formulation Expansion

The formulation business has an export-heavy profile and could provide a higher-value growth opportunity if international sales continue expanding.

Specialty-Chemical Performance

The specialty-chemicals and intermediates businesses provide additional revenue streams beyond APIs and formulations.

Domestic Pharmaceutical Demand

India's growing healthcare requirements and pharmaceutical consumption can provide a long-term demand backdrop for API and formulation manufacturers.

Cost Management

Raw materials, energy, logistics and manufacturing costs can materially influence margins.

Maintaining cost discipline will be important if the company wants EBITDA growth to translate into stronger PAT growth.

Aarti Drugs Share Price Target

A specific Aarti Drugs share price target should be viewed as an estimate rather than a guaranteed future price.

The stock was around ₹418.55 on August 28, compared with a 52-week high of approximately ₹534.15.

The current market price needs to be assessed against earnings growth, valuation, pharmaceutical-sector conditions and the company's future profitability.

Rather than assuming that the stock will return to its previous high, investors should look for evidence of sustained EPS growth and improving return ratios.

Is Aarti Drugs a Good Stock to Buy?

The latest results contain both positive and negative signals.

Revenue increased 19% year over year, while EBITDA rose around 30% and the EBITDA margin improved.

However, PAT declined approximately 7% year over year.

That means the company's operating performance is improving, but the benefit has not yet fully reached the bottom line.

Aarti Drugs also has a diversified business model spanning APIs, formulations, specialty chemicals and intermediates.

For investors, the key question is whether the company can convert its improving operating performance into consistent earnings growth.

Calling the stock an automatic "buy" based on revenue growth alone would therefore be too simplistic.

How Should Investors Track Aarti Drugs Share Price?

Anyone monitoring the Aarti Drugs share price should look beyond daily price movements.

Useful indicators include API sales volumes, product-wise revenue, formulation growth, export performance, EBITDA margin, raw-material costs, working capital, capex, debt and cash flow.

The company's investor-relations portal provides quarterly reports, investor presentations, press releases and other filings for investors.

Recent corporate disclosures also include the Q1 FY27 investor presentation and updates concerning the Sayakha plant.

Investors researching the pharmaceutical sector can also use market-analysis resources from Jainam Finance to understand sector trends, valuation and broader investment concepts.

Frequently Asked Questions

What is the Aarti Drugs share price today?

Aarti Drugs was trading around ₹418.55 on August 28, 2026, according to available market data.

What is the NSE symbol of Aarti Drugs?

The NSE symbol is AARTIDRUGS, while the BSE code is 524348.

What is the 52-week high and low of Aarti Drugs?

The recent 52-week range is approximately ₹318.60 to ₹534.15.

How were Aarti Drugs' latest quarterly results?

For Q1 FY27, consolidated revenue from operations was approximately ₹702.78 crore, while EBITDA was ₹96.9 crore and PAT was around ₹50.13 crore.

Did Aarti Drugs' revenue increase?

Yes. Consolidated revenue from operations increased approximately 19% year over year in Q1 FY27.

Did net profit increase?

No. Consolidated PAT declined approximately 7% year over year to around ₹50.13 crore.

What does Aarti Drugs manufacture?

The company operates across APIs, formulations, specialty chemicals and intermediates.

What could drive future growth?

API demand, formulation exports, specialty chemicals, domestic pharmaceutical consumption, improved margins and better cost management could support future growth.

Is Aarti Drugs suitable for long-term investment?

The company has a diversified pharmaceutical and chemical business and delivered strong revenue and EBITDA growth in Q1 FY27. However, investors should consider profit trends, regulatory developments, raw-material costs, valuation and cash flow before making a long-term investment decision.

Final Thoughts

The Aarti Drugs share price reflects a company that is showing healthier operating momentum but still has some work to do at the bottom-line level.

Q1 FY27 revenue grew around 19% and EBITDA increased approximately 30%, with the EBITDA margin improving to about 13.8%. However, PAT declined around 7% year over year, showing that stronger operating performance has not yet translated into equivalent net-profit growth.

The company's diversified exposure to APIs, formulations, specialty chemicals and intermediates provides several potential growth avenues. Its domestic business remains important, while formulation exports offer additional international exposure.

For investors researching AARTIDRUGS, the key factors are API demand, formulation growth, export performance, EBITDA margins, raw-material costs, specialty-chemical sales, regulatory compliance, capex, debt and cash flow. Jainam Finance can provide useful market and investment resources, but investors should conduct independent research before making any investment decision.

Disclaimer: This article is for educational and informational purposes only and should not be considered investment advice. Pharmaceutical and specialty-chemical stocks can be affected by regulatory changes, pricing pressure, raw-material costs, currency movements and industry cycles. Past performance does not guarantee future returns.